June 6, 2011
With the next generic drug price listing scheduled for June, manufacturers are under increasing pressure to decide whether to apply for NHI pricing for generic versions of Takeda Pharmaceutical's type 2 diabetes treatment Actos (pioglitazone). Since the validity and interpretation...read more